Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baxdrostat + dapagliflozin versus dapagliflozin alone in chronic kidney disease with hypertension
2023-506457-38-00Phase 3Authorised
- Sponsor
- AstraZeneca
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 38
01
Overview
Phase 3, randomised, double-blind trial in chronic kidney disease (CKD), hypertension (HTN) and cardiac morbidity comparing Baxdrostat + dapagliflozin with Dapagliflozin + baxdrostat placebo (2 arms). Primary endpoint: Primary endpoint: Change from baseline in eGFR to post-treatment. Planned start May 2024; status: authorised.
02
Drugs
baxdrostat
03
Conditions
chronic kidney disease (CKD)hypertension (HTN)cardiac morbidity
Beyond the preview
Go deeper on 2023-506457-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506457-38-00.